|Bid||7.38 x 800|
|Ask||8.41 x 1000|
|Day's Range||8.13 - 8.44|
|52 Week Range||5.06 - 14.34|
|Beta (5Y Monthly)||2.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2022 - Nov 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.38|
Subscribe to Yahoo Finance Plus to view Fair Value for EOLS
NEWPORT BEACH, Calif., September 21, 2022--Evolus celebrates the conclusion of certain royalty payments that resulted from the 2021 settlement of litigation claims.
In this article, we will discuss the 13 stocks to sell now according to billionaire Larry Robbins. If you want to skip the detailed analysis of Robbins’ investment philosophy, go directly to 5 Stocks to Sell Now According to Billionaire Larry Robbins. American investor and philanthropist Larry Robbins was born in 1969. Glenview Capital Management, […]
Evolus, Inc. is small-cap company rapidly taking market share in the growing "aesthetic neurotoxin" space -- a.k.a. Using the April $10 call strikes, fashion a covered call order with a net debit in the $7.60 to $7.80 a share range (net stock price - option premium).